Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2026-04-03 21:30:11 ET · period of report 2026-04-01 · accession 0001636282-26-000030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-03 21:30 | 2026-04-01 | SYRE | Sloan Sheldon | Chief Medical Off | M - OptEx | $21.66 | +7,958 | 7,958 | New | +$172.4K |
| DT | 2026-04-03 21:30 | 2026-04-01 | SYRE | Sloan Sheldon | Chief Medical Off | S - Sale+OE | $50.00 | -7,958 | 0 | -100% | -$397.9K |
| DT | 2026-04-03 21:30 | 2026-04-01 | SYRE | Sloan Sheldon | Chief Medical Off | M - OptEx | $0.00 | -7,958 | 87.5K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-01 | M | A | 7,958 | $21.66 | 7,958 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. |
| 2 | Common | Common Stock | 2026-04-01 | S | D | 7,958 | $50.00 | 0 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-04-01 | M | D | 7,958 | $0.00 | 87,542 | D | $21.66 · — to 2035-01-15 | 7,958 Common Stock | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. (F2) This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. |